Jennerex Out-Licenses China Rights for Cancer Drug to Lee’s Pharma

Jennerex, Inc., a clinical-stage biotherapeutics company with a novel virus-based treatment for cancer, has licensed the China rights for JX-594 to Lee’s Pharmaceuticals. Jennerex is headquartered in San Francisco, though its R&D operations are in Ottawa, Canada. JX-594 is currently undergoing a Phase II trial to treat hepatocellular carcinoma (HCC), an urgent unmet need in China. More details... Stock Symbol: (HKEX: 8221)